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Background: Invasive mould diseases are associated with high morbidity, mortality 
and economic impact. Its treatment is often started prior to differential pathogen 
diagnosis. Isavuconazole is approved for treatment of invasive aspergillosis (IA) and 
invasive mucormycosis (IM) when amphotericin-B is not indicated.
Objectives: To estimate the cost-effectiveness of isavuconazole vs voriconazole for 
the treatment of adult patients with possible IA prior to differential pathogen diag-
nosis, in Spain.
Methods: A decision tree analysis was performed using the Spanish Healthcare 
System perspective. Among all patients with possible IA, it was considered that 7.81% 
actually had IM. Costs for laboratory analysis, management of adverse events, hos-
pitalisation and drugs per patient, deaths and long-term effects in life years (LYs) and 
quality-adjusted LYs (QALYs) were considered. Efficacy data were obtained from clini-
cal trials and utilities from the literature. Deterministic and probabilistic sensitivity 
analyses (PSA) were conducted.
Results: In patients with possible IA and when compared to voricanozole, isavucona-
zole showed an incremental cost of 4758.53€, besides an incremental effectiveness 
of +0.49 LYs and +0.41 QALYs per patient. The Incremental Cost Effectiveness Ratio 
was 9622.52€ per LY gained and 11,734.79€ per QALY gained. The higher cost of 
isavuconazole was due to drug acquisition. Main parameters influencing results were 
mortality, treatment duration and hospitalisation days. The PSA results showed that 
isavuconazole has a probability of being cost-effective of 67.34%, being dominant in 
24.00% of cases.
Conclusions: Isavuconazole is a cost-effective treatment compared to voriconazole 
for patients with possible IA for a willingness to pay threshold of 25,000€ per ad-
ditional QALY.
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1  |  INTRODUC TION
Invasive mould diseases (IMD) are life-threatening infections, espe-
cially in immunocompromised patients such as those with haema-
tologic diseases, those who have been subjected to a solid organ 
transplantation or haematopoietic stem cell transplantation (HSCT) 
and in critically ill patients with leukaemia or profound neutropaenia.1,2 
IMDs are caused by fungus of the genus Aspergillus (causing invasive 
aspergillosis, IA) or other filamentous fungi, for example, Mucorales 
(causing invasive mucormycosis, IM). These infections entail an im-
portant clinical burden to individuals who are already vulnerable as 
they are associated with high morbidity and mortality, with mortality 
rates ranging from 30% to 80% for IA and up to 97% when untreated 
IM.3,4 Similarly, a delay in the establishment of an adequate therapy 
leads to increased mortality rates in certain type of patients and sig-
nificant increase in treatment duration.5 For instance, according to a 
study analysed by the FDA, a delay of 6 days in the initiation of treat-
ment, increased mortality rates up to almost two times, from 48.6% 
to 82.9%.6 IMDs have a high economic impact as well.1,7,8 In line with 
available data in the website of the Spanish Ministry of Health RAE-
CMBD (Registro Atención Especializada- Conjunto Mínimo Básico de 
Datos),9 length of stay for IA in Spain in 2017 was 54.20 days and the 
mean associated costs were 18,235€; regarding IM the length of stay 
was 70 days and the mean costs were 24,020€.
Even though it is highly important to establish an early diagnosis 
for this pathology, the process is challenging because often non-spe-
cific symptoms are present. According to the recently published up-
date of the consensus definition of invasive fungal disease (IFD) from 
the EORTC and the Mycoses Study Group Education and Research 
Consortium, probable IFD requires the presence of a host factor, a 
clinical feature and mycologic evidence; cases that meet the criteria 
for a host factor and a clinical feature but for which mycological evi-
dence has not been found are considered possible IMD.10 In contrast, 
obtaining a diagnosis of mucormycosis on histomorphological basis is 
challenging, and the most common cause for incorrect morphological 
diagnosis is the misidentification of Mucorales as Aspergillus spp. The 
application of immunohistochemistry or PCR techniques on either 
fresh or formalin-fixed paraffin-embedded tissue have been shown 
to be highly specific, although a variation in sensitivity has been re-
ported.11 The outcome and the management of the patient depend on 
a prompt and correct diagnosis and usually treatment is initiated be-
fore pathogen identification.3 However, if the treatment turns out to 
be inappropriate, a delay in receiving the right treatment can increase 
the mortality rate, as reported by Chamilos et al where a 6-day delay 
was associated with a 2-fold increase in mortality rate.12
Among the therapeutic options currently available to treat IA and 
IM, only isavuconazole and amphotericin-B (L-AMB) have approved in-
dication for both types of infections. Voriconazole and posaconazole 
are exclusively indicated for the treatment of IA, particularly po-
saconazole is only indicated when the disease is refractory to L-AMB. 
According to published therapeutic guidelines, isavuconazole is recom-
mended as a rescue therapy in IM patients, as well as posaconazole, 
although the recommendation for posaconazole is off-label.11
The SECURE pivotal trial13 has shown isavuconazole to have 
non-inferior efficacy and survival to voriconazole, and better safety 
profile, in patients with IA. On the other hand, the VITAL trial has 
demonstrated the efficacy of isavuconazole as primary therapy, in 
refractory patients and salvage, in the treatment of IM.14
Isavuconazole, on top of its broad spectrum, being active against 
Aspergillus and Mucorales, which is a clear advantage when treating 
patients with possible IA (thus, lacking pathogen confirmation), of-
fers several additional advantages relative to voriconazole, that en-
tail benefits to the patients and could carry economic consequences 
as well; it has lower drug-drug interactions; therefore, it can be more 
safely given to patients receiving additional medications; isavuco-
nazole does not need routinely therapeutic drug monitoring, as it is 
the case for voriconazole; patients receiving it show fewer adverse 
events, and dose adjustment is not needed for patients with mild/
moderate hepatic impairment or renal impairment.15,16
Several economic analyses of isavuconazole vs voriconazole for 
the treatment of IA have been conducted in different countries: in 
hospitalised patients with IA in the United States17 and in patients 
with possible IA in Sweden18 and the UK.19 Cost-minimisation mod-
els of isavuconazole vs L-AMB followed by posaconazole for the 
treatment of IM have been also performed in Italy,20 Germany21 
and the UK.22 The clinical situation described in the UK cost-effec-
tiveness model19 clearly reflects the real-world treatment approach 
in Spain when facing patients with possible IA, in which is neces-
sary to start treatment before getting the differential diagnosis be-
tween IA and IM. Although isavuconazole is more expensive than 
voriconazole, it is effective for both IA and IM and has a better safety 
profile. Therefore, the objective of the present study was to conduct 
a health economic analysis from the Spanish National Health Service 
perspective (NHS), by estimating the cost-effectiveness of isavuco-
nazole vs voriconazole, the standard of care in Spain, for the initial 
treatment of IMD prior to differential diagnosis between IA and IM.
2  |  MATERIAL S AND METHODS
2.1  |  Economic model
A cost-effectiveness and cost-utility analysis, with a lifetime horizon 
and from the perspective of the NHS, was adapted to Spain.19 In order 
to reflect the short-term patient pathway from initial symptoms to 
eventual result after antifungal treatment (resolution of infection or 
K E Y W O R D S
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death), a decision tree originally developed with the collaboration of 
UK expert's panel was analysed by local experts (1 hospital pharmacist, 
1 clinical pharmacologist and 1 haematologist, from three different au-
tonomous communities of Spain) and considered a representative ap-
proach of Spanish patients’ pathology pathways (Figure 1).
First, the model reflects that a population of patients with ‘possible 
IA’ can either be treated with isavuconazole or voriconazole. Secondly, 
patients are subdivided into having IA or IM, regardless of a clinical con-
firmation. In this step, a prevalence of 7.81% was used to estimate those 
patients incorrectly diagnosed with possible IA but actually having IM 
instead (tree branches with blue dots in Figure 1). Due to a lack of spe-
cific data from Spain, this prevalence was estimated from a UK study.23
Then, depending on treatment response, discontinuations or di-
agnostic confirmation, patients may switch to a second-line treat-
ment or stay with the current treatment. Second-line treatment is 
L-AMB (as recommended in clinical guidelines24), followed by oral 
posaconazole or oral voriconazole.
Eventually, the model considers the possibility of having patho-
gen confirmation, that was set on the 11th day of treatment (which is 
the median time between clinical signs and IM diagnosis observed by 
Xhaard et al25 and for 50% of patients - set with the experts’ panel). 
Regarding all IA patients and those IM patients treated with isavu-
conazole, pathogen confirmation does not affect the patient flow.
However, all IM patients with pathogen confirmation in 
the voriconazole arm will switch to second-line treatment, as 
voriconazole is not indicated for the treatment of mucorales.26 
Patients having IM and not switching are those who failed in getting 
a pathogen confirmation and therefore, for a short extra period of 
time (see treatment durations and Figure 1) they remain with inap-
propriate treatment.
2.2  |  Clinical inputs
2.2.1  |  Second-line treatment
The percentage of patients receiving second-line treatment was 
calculated using data from the SECURE and VITAL trials by consid-
ering the number of patients that discontinued first-line treatment 
due to no or insufficient response to treatment, adverse events or 
F I G U R E  1  Decision tree model structure. IA, Invasive aspergillosis; IM, Mucormycosis; L-AMB, Liposomal amphotericin-B
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intercurrent illness.13,14 Since no statistically differences were found 
between isavuconazole and voriconazole, these percentages were 
equally applied for both therapies (Table 1).
Accordingly, 27.13% of IA patients and 14.29% of IM patients 
treated with isavuconazole will switch to a second-line treatment. 
In case of pathogen confirmation, 100% of IM patients treated with 
voriconazole will switch to a second-line treatment.
2.2.2  |  All-cause mortality
All-cause mortality over 84-day from the SECURE trial13 (Table 1) 
was used to approximate mortality rate in IA patients, regardless 
of the initial treatment (isavuconazole or voriconazole) since no 
statistical differences were reported in the trial. In order to avoid 
double counting in the number of deaths, this mortality was also 
assumed for patients with IA that switch to L-AMB.
The 84-day all-cause mortality in IM patients treated with isavu-
conazole was extracted from the VITAL study14 (Table 1). According 
to published data,12 an increased mortality probability due to a delay 
in the correct treatment was applied to IM patients treated with 
voriconazole that switch to L-AMB. On the other hand, patients lack-
ing pathogen confirmation were assumed to have the same mortality 
as untreated patients6 (Table 1).
2.3  |  Treatment regimens, dosing and duration
2.3.1  |  Dosing
Dosing of all treatments in the model was aligned to their corre-
sponding SmPC (refs FT) and, for L-AMB, the FungiScope™ matched 
control study14 to reflect real-world dosing (Table 2). For calcula-
tions, weight distribution of the general Spanish population was 
used, according to the age range of patients included in the SECURE 
study,13,27 51.10 (±16.20) years for isavuconazole and 51.20 (±15.90) 
for voriconazole. We then used the weighted average for 3 sub-
groups (35-44 years, 45-54 years and 55-64 years).
The model considers that, according to VITAL study data,14 75% 
patients will start with IV treatment and subsequently step-down 
to oral therapy, while the remaining 25% will directly start with oral 
therapy.
Second-line treatment consists of IV L-AMB followed by oral 
voriconazole/posaconazole at a 50%/50% ratio, except for IM pa-
tients treated with voriconazole that switch to L-AMB: in this case, 
only oral posaconazole is considered. In IA, oral voriconazole was 
included as step-down therapy after L-AMB as fungal load is signifi-
cantly reduced after therapy with L-AMB and thus voriconazole is 
efficacious again (expert panel input).
2.3.2  |  Duration
Treatment durations are summarised in Figure 1 and Table 1. For IA 
patients, it was calculated by adjusting isavuconazole treatment du-
ration in the SECURE study (47.0 days in total: 8.1 days IV, 38.9 days 
oral)28 according to whether patients responded to, and remained 
on, first-line treatment or discontinued treatment and switched to 
second-line therapy. Since no statistical differences among thera-
pies were found, a total treatment duration of 70.70 days for IA 
was assumed for both therapies. As previously published, the dura-
tion of second-line therapy was assumed to be equal to the dura-
tion of first-line therapy in patients who responded to treatment 
(70.70 days).29













Full coursec  ISAV/VORI - 70.70
Mucormycosis
1st line ISAV 14.29% 42.86% 21.00
1st line VORI 100%a  82.86% 11.00b 
2nd line L-AMB + POSA - - 213.00
Full coursec  ISAV - 42.86% 213.00
Full coursec  VORI - 96.20% 47.00
Abbreviations: ISAV, Isavuconazole; L-AMB, Liposomal Amphotericin-B; Pts, Patients; VORI, 
Voriconazole.
aOf those who have pathogen confirmation;a 
bChange to second line after pathogen confirmation;b 
cPatients maintaining 1st line treatment until resolution or death.c 
TA B L E  1  Clinical inputs
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Switch to second-line treatment was assumed in the 21th treat-
ment day (at the end of first quarter of an 84-day therapy course). 
Accordingly, a patient with IA starting with voriconazole and who 
must switch to second-line therapy would therefore be on treatment 
for 21.00 + 70.70 days. Specifically, L-AMB treatment was assumed 
to last 14.50 days30 and oral posaconazole/voriconazole 56.20 days, 
calculated by subtracting 14.50 to the overall second-line treatment 
duration (70.70 days).
For IM patients, total treatment duration was adjusted as for IA 
but using data from the VITAL study (15.5 days IV, 133.5 days oral, or 
149 days for those not receiving IV). Therefore, total treatment dura-
tion for IM patients receiving isavuconazole was set as 213.00 days. 
The same assumptions regarding the duration of second-line IV and 
step-down therapy were made as for IA. The duration of L-AMB 
was set to 27.20 days, as observed in the matched cohort from the 
FungiScope™ registry.31 Then, the duration of posaconazole treat-
ment (185.80 days) was calculated subtracting L-AMB treatment 
days to the total duration of second-line therapy.
According to the model, IM patients treated with voriconazole 
and with pathogen confirmation switch treatment after 11.00 days,25 
meaning patients are treated over 11.00 + 213.00 days. Whereas in 
patients lacking confirmation, the total treatment duration was as-
sumed to be 47.00 days.28
2.4  |  Costs
Only direct costs were included in the model, namely: drug acquisi-
tion, hospitalisations, adverse events (AEs) and laboratory analysis. 
All costs were expressed as 2020 Euros.
2.4.1  |  Drug acquisition costs
Acquisition costs (Table 2) were estimated using the ex-factory price 
(EFP)32 including the corresponding mandatory deduction outlined 
in Royal Decree 08/201033 and the reference price34,35 established 
or the lowest EFP among the available.
2.4.2  |  Hospitalisations
The cost per hospital day used in the model was 568.48€. This was 
calculated from Spanish health system reference costs as the mean 
of the latest published prices for hospital stay in every autonomous 
community.36
Length of hospitalisation stay for IA patients was extracted from 
the SECURE study.13,28 Since no statically differences were found 
between isavuconazole and voriconazole, isavuconazole's mean 
hospitalisation length stay, 18.60 days, was used for both therapies. 
This duration was also assumed to second-line therapy.
IM patients with a full course treatment of either isavuconazole 
or voriconazole were assumed to have the same hospital stay length 
as reported in the VITAL study,14 19.30 days. In the second-line 
treatment, according to the mean duration of IV therapy observed in 
the FungiScope™ case-control study,31 it was assumed that patients 
remain hospitalised during the IV treatment, which was previously 
set as 27.20 days (see treatment durations).
For IM patients treated with voriconazole but switching because of 
pathogen confirmation, patients were assumed to be hospitalised for 
the entire course of their treatment prior to switching (11 days) plus the 
second-line treatment hospitalisation previously detailed (27.20 days).
TA B L E  2  Treatment dosing and costs
Treatment
Price per pack 
(€)32-35 Pack size32







Intravenous (Day 1 & 2) 384.00 1.00 384.00 3.00 600 mg
Intravenous (Day 3 onwards) 384.00 1.00 384.00 1.00 200 mg
Oral (Day 1 & 2) 672.00 14.00 48.00 6.00 600 mg
Oral (Day 3 onwards) 672.00 14.00 48.00 2.00 200 mg
Voriconazole
Intravenous (Day 1) 79.99 1.00 79.99 6.00 1200 mg
Intravenous (Day 2 onwards) 79.99 1.00 79.99 4.00 800 mg
Oral (Day 1) 214.51 28.00 7.66 8.00 800 mg
Oral (Day 2 onwards) 214.51 28.00 7.66 4.00 400 mg
Liposomal Amphotericine B
Intravenous (IA) 834.99 10.00 83.50 8.00 400 mg
Intravenous (IM) 834.99 10.00 83.50 8.00 400 mg
Posaconazole
Oral (Day 1) 399.60 24.00 16.65 6.00 600 mg
Oral (Day 2 onwards) 399.60 24.00 16.65 3.00 300 mg
Abbreviations: IA, Invasive aspergillosis; IM, Invasive mucormycosis.
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2.4.3  |  Adverse events
The model includes adverse events reported in the SECURE study15 
for which statistically significant differences between isavuconazole 
and voriconazole treatments were found (see Table 3). For the treat-
ment with L-AMB, unlike the UK original model, nephrotoxicity37 
(associated with 9 days of additional hospital treatment29) and hy-
pokalaemia38 were also considered. All the costs of adverse events 
were calculated from Spanish health system reference costs as the 
mean of the latest published prices for related specialist outpatient 
visit in autonomous communities.36 Due to a lack of specific infor-
mation, hypokalaemia cost was assumed to correspond to a nephrol-
ogy specialist visit cost (206€).36 Importantly, the model adjusted 
the average calculated AE costs by the duration of treatment for 
every patient subgroup.
2.4.4  |  Laboratory tests
Laboratory monitorisation tests were estimated taking into account 
length of treatment, adverse events and precautions included in the 
summary of product characteristics of each drug26 (Table 3). Liver 
function test was performed twice a week in all treatment groups 
and both for IA and IM.13,14,24,26 Same applied for therapeutic drug 
monitoring (TDM) which was performed once a week.39 In the sensi-
tivity analysis, a scenario where 10.00% of isavuconazole's patients 
would be monitored was analysed.39 Finally, for those patients hav-
ing IM and treated with L-AMB the model includes serum creati-
nine tests twice a week.13,14,24,26 All the costs of laboratory tests 
were calculated from Spanish health system reference costs as the 
mean of the latest published prices for related test in autonomous 
communities.36
TA B L E  3  Costs included in the model
System organ class Adverse event
Incidence of adverse event15
Cost (€) per 
event36Isavuconazole Voriconazole
Eye disorders Visual impairment 0.40% 5.80% 52.00
Reduced visual acuity 0.00% 1.50% 52.00
Hepatobiliary disorders Hyperbilirubinaemia 0.40% 2.30% 133.58
Abnormal hepatic function 0.80% 3.50% 133.58
Hepatic failure 0.00% 1.20% 133.58
Jaundice 0.00% 0.80% 133.58
Cholestasis 0.00% 1.20% 133.58
Laboratory Tests Increased GGT 2.30% 5.40% 157.82
Increased ALP 1.90% 4.20% 157.82
Increased AST 1.90% 4.20% 157.82
Increased ALT 1.60% 4.20% 157.82
QT prolonged 0.40% 3.10% 157.82
Psychiatric disorders Hallucination 0.40% 4.20% 156.35
Visual hallucination 0.00% 3.50% 156.35
Respiratory. thoracic and mediastinal 
disorders
Dyspnoea 3.10% 0.80% 127.51
Liposomal Amphotericine B
Renal disorders Nephrotoxicity37 19.50%  740.96
Metabolism and nutritional 
disorder
Hipokalaemia38 53.80% 206.00
Laboratory Analysis13,14,24,26,38 Nº per week Pathology Unitary cost €36
Liver function test 2.00 IA & IM 14.78
Therapeutic drug monitoring of 
antifungal
1.00 IA & IM 107.98
Serum creatininea  2.00 IM 1.80
Other costs Unitary cost €36 Unitary cost €36
Hospitalisation day36 568.48
Abbreviations: IA, Invasive aspergillosis; IM, Mucormycosis.
aOnly for patients treated with L-AMB.a 
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2.5  |  Utility and life expectancy
Utility and life expectancy were defined using the most frequent un-
derlying condition of IMD in the SECURE and VITAL trials, which is 
acute myeloid leukaemia. Therefore, utility was assumed to be 0.82, 
as reported by Leunis A et al40 and a life expectancy of 17.00 years 
reported by Bower et al41 was used. This figure was then discounted 
using a 3.00% rate42 and the present value factor sum method re-
sulting in an average discounted life expectancy of 13.56 years.
2.6  |  Cost-effectiveness outcomes
Results are presented through the main cost-effectiveness metric 
which is the incremental cost-effectiveness and cost-utility ratio 
(ICER/ICUR). To calculate it, both long-term effects in life years (LYs) 
and quality-adjusted life years (QALYs) were reported.
Costs and outcomes were discounted using a 3.00% discount 
rate.42 Results of the analysis were checked using a willingness to 
pay (WTP) threshold of 25,000 Euros per additional QALY gained.43 
Thus, the evaluated strategy is considered cost-effective when the 
ICUR < 25,000 €/QALY.
2.7  |  Sensitivity analysis
Sensitivity analyses were performed in order to evaluate the robust-
ness of the model and analyse the uncertainty around the param-
eter's estimates and assumptions.
2.7.1  |  Deterministic sensitivity analysis
A deterministic sensitivity analysis was conducted to analyse the fol-
lowing parameters: costs, mortality, quality of life, epidemiology and 
life expectancy, treatment, clinical practice, laboratory analysis and 
hospitalisation. In the analysis upper and lower values for param-
eters bounded between 0 and 1 were limited between their bound-
ing figures. For each variable, upper and lower bounds of +20% and 
–20%, respectively, were assessed.
2.7.2  |  Probabilistic sensitivity analysis
A probability distribution was defined for each parameter accord-
ing to the nature of the data: parameters bounded by 0 and 1, such 
as percentages and health utilities, were given a beta distribution; 
parameters with positive figures and bounded at 0 (i.e. costs) were 
given a gamma distribution. The model was run repeatedly 10,000 
times, taking each time a randomly selected value for each of the 
different inputs from its respective probability distribution (Monte 
Carlo simulations). Mean costs and mean QALYs were calculated 
using these values and results were subsequently summarised.44
The authors confirm that the ethical policies of the journal, as 
noted on the journal's author guidelines page, have been adhered to. 
No ethical approval was required as the research in this article re-
lated to an economic model based on data from published literature.
3  |  RESULTS
3.1  |  Base case
In the situation considered in this economic model, which is the 
treatment of IMD prior to differential diagnosis between IA and IM, 
at the point of treatment initiation, isavuconazole delivered 0.49 
more LYs and 0.41 more QALYs per patient than voriconazole at an 
incremental cost of 4,759.53€. The ICER and ICUR were 9,622.52€/
LY gained and 11,734.79€/QALY respectively (Table 4). The higher 
cost of isavuconazole is mainly due to drug acquisition costs since 
the rest of direct costs considered (management of adverse events, 
laboratory tests and hospitalisation days) are reduced when using 
isavuconazole in comparison to voriconazole.
Regarding LYs and QALYs, the differences between these two 
comparators were mostly due to the different effects of the treat-
ments in patients with IM (higher mortality rates among patients 
with IM treated with voriconazole compared with those treated 
with isavuconazole). Importantly, isavuconazole was associated 
with a significant reduction of 10.79% deaths and 52.95% adverse 
events.
3.2  |  Deterministic sensitivity analysis
Values for 122 parameters were tested in the deterministic sensi-
tivity analysis. As shown in Figure 2, main parameters influencing 
results were mortality, treatment duration and number of hospitali-
sation days. It was seen that results were especially sensitive to a 
reduction in mortality of IA patients treated with isavuconazole in a 
20%, or an increase of this same input for voriconazole in the same 
percentage; the ICER was decreased to 2,600€/QALY. Additionally, 
treatment length of IA patients and length of hospital stay did have 
also important influence in the results. An increase in the number of 
hospital days for isavuconazole by 20% or a decrease for voricona-
zole, doubled the ICERs.
3.3  |  Probabilistic sensitivity analysis
In the probabilistic sensitivity analysis, the average ICUR was com-
pared with a WPT of 25, 000€ per QALY.43 Results showed that 
65.36% of simulations (that represent the differences in costs and 
effects between comparators) were in the top right quadrant, indi-
cating that isavuconazole is more efficient and more expensive in 
most of the cases. Besides, 24.00% of the simulations were domi-
nant meaning more health gains and less expensive (Figure 3).
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Data were represented in a cost-effectiveness acceptabil-
ity curve (CEAC) in order to estimate the probability of isavuco-
nazole of being cost-effective for a range of WPT ranging from 0 
to 100,000€/QALY (Figure 4). According to these results, isavuco-
nazole has a probability of 67.34% of being cost-effective for a WPT 
of 25, 000€/QALY.
4  |  DISCUSSION
Invasive mould diseases are very severe infections that have a high 
morbidity and mortality, entailing high associated costs. The early 
differential diagnosis between IA and IM is very challenging, so in 
real life setting usually treatment is initiated before pathogen iden-
tification, because a delayed treatment initiation can severely influ-
ence the outcomes.5 Under these circumstances, isavuconazole and 
voriconazole are two main therapeutic options that can be chosen 
by the physician, taking into account both clinical and economic fac-
tors, however, only isavuconazole is effective and indicated for treat-
ing both IA and IM.13,14,26 Taking into consideration this context, this 
modelling study was undertaken to compare, from the Spanish NHS 
perspective, the cost-effectiveness of the use of isavuconazole vs the 
standard of care, voriconazole, when at the time of therapy initiation, 
the differential diagnosis between IA and IM has not been achieved.
F I G U R E  2  Deterministic sensitivity analysis. IA, Invasive Aspergillosis; ICUR, Incremental cost-utility ratio; IM, Mucormycosis; Isa, 
Isavuconazole; QALY, Quality-adjusted life years; Vori, Voriconazole
TA B L E  4  Base case analysis results
Isavuconazole Voriconazole
DifferenceIA IM Combined IA IM Combined
Costs (€) €
Drug 10, 824.92 2,058.46 12, 883.37 6,352.79 1,291.34 7,644.14 5,239.24
Hospital 15, 841.83 1,240.52 17, 082.35 15, 841.83 1,277.27 17, 119.10 −36.74
AEs 374.45 17.63 392.08 422.71 58.14 480.85 −88.77
Laboratory analysis 291.03 55.20 346.24 673.82 26.61 700.43 −354.20
Total costs 27, 332.24 3,371.80 30, 704.04 23, 291.15 2,653.36 25, 944.52 4,759.53
Effects
AEs (%) 33.14 2.10 35.25 69.84 5.08 74.91 −39.67
Deaths (%) 26.80 3.35 30.15 26.80 7.00 33.79 −3.65
LY 8.87 0.61 9.47 8.87 0.11 8.98 0.49
QALY 7.27 0.50 7.77 7.27 0.09 7.36 0.41
ICER per LY gained (€/LY) 9,622.52
ICUR per QALY gained (€/QALY) 11, 734.79
Abbreviations: AEs, Adverse events; IA, Invasive aspergillosis; ICER, Incremental cost-effectiveness ratio; ICUR, Incremental cost-utility ratio; IM, 
Mucormycosis; LYs, Life year gains; QALY, Quality-adjusted life years.
74  |    AZANZA et Al.
The base case analysis suggests that isavuconazole is cost-effec-
tive compared with voriconazole at a WTP threshold of 25,000€/
QALY. Although there is not a specific WTP threshold to be applied 
in health economic analyses in Spain, it has been proposed a range 
between 25, 000 and 60, 000 € per additional QALY gained,43,45 
meaning the analysis was made using the more conservative pub-
lished threshold.
While isavuconazole is 8.23% more expensive than 
voriconazole, it is also associated with an increase of 0.41 QALYs 
and 0.49 LYs per patient. Regarding the economic cost, the main 
difference is the drug acquisition cost (12, 883.37€ per patient 
for isavuconazole vs 7,644.14€ for voriconazole), but these costs 
are partially compensated by a reduction in hospitalisation, lab-
oratory analysis and adverse event costs, because of clinical 
outcomes improvement. Treatment with isavuconazole was also 
associated with a 10.79% reduction in deaths and an import-
ant reduction in adverse events (52.95%) when compared with 
voriconazole.
F I G U R E  3  Probabilistic sensitivity analysis. WTP threshold 25 000€. QALY, Quality-adjusted life years; WTP, Willingness to pay 
threshold
F I G U R E  4  Cost-effective acceptability curve. QALY, Quality-adjusted life years
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The results of the original UK model,19 in which this analysis 
was based, also favoured the use of isavuconazole with 0.39 QALYs 
and 0.48 more LYs per patient than voriconazole at an incremental 
cost of 3,228£, resulting in an ICUR of 8,242£ per additional QALY 
gained and an ICER of 6,759£ per additional LY gained. This was 
mainly due to the efficacy of isavuconazole against IA and IM, as 
opposed to voriconazole, which is only effective against IA. The 
small difference in QALYs and LYs between the original UK model 
and the present model is due to the different discount rate applied 
to the life expectancy: 3.5% in the UK model and 3% in the present 
one. According to the deterministic sensitivity analysis, the model 
was primarily sensitive to IA patients’ mortality, treatment dura-
tion and number of hospital days. The results of the Spanish model 
described in this paper are, therefore, well-aligned with the previ-
ously published UK model as both are favourable to isavuconazole 
in the treatment of IA prior to differential pathogen diagnosis.
Other economic analysis comparing isavuconazole vs 
voriconazole in different settings have achieved similar results, 
highlighting the favourable cost-effectiveness results of isavuco-
nazole. A study conducted in the US comparing, from the hospital 
perspective, isavuconazole vs voriconazole in first-line treatment 
of patients with IA,17 showed that isavuconazole was associated 
with a 7,418$ lower total cost per patient than voriconazole. 
Results were robust in the deterministic sensitivity analysis, with 
isavuconazole being dominant vs voriconazole in most cases, as 
well as in probabilistic sensitivity analysis where isavuconazole 
was cost-effective in 82.00% of the simulations at the $50, 000 
WTP threshold. A cost-effectiveness analysis conducted from 
Swedish healthcare payer perspective18 achieved similar results of 
this study: isavuconazole resulted in an ICUR of 174, 890 Swedish 
krona (SEK) per additional quality-adjusted life year (QALY) 
gained. Sensitivity analyses of this model showed that the average 
ICUR consistently fell below the WTP threshold of 1, 000, 000 
SEK. Deterministic analysis showed that the model was primarily 
sensitive to mortality.
To test the uncertainty of the parameters and, therefore, the ro-
bustness of the model results, a range of sensitivity analyses were 
performed. In the deterministic sensitivity analysis, it was found that 
the results were robust under a series of alterations in the main pa-
rameters. The model was sensitive to changes in mortality of IA pa-
tients, length of treatment and hospital stay. This analysis shows the 
dependence of the results on the model inputs and underlying cases 
around the treatment of IA patients. Interestingly, all the results of 
the deterministic sensitivity analysis stayed below the 25, 000€/
QALY threshold.
Results of the probabilistic sensitivity analysis, scattered mainly 
in the upper and lower right quarters, show the uncertainty about 
the parameters used in the model. The observed uncertainty along 
the horizontal axis (QALY) is mainly due to the small size of the 
samples. However, according to the CEAC, the probability of being 
cost-effective was 67.34% with a WTP threshold of 25, 000€/QALY 
and increases up to 82.08% with a WTP threshold of 60, 000€/
QALY, which is the range of the proposed threshold for Spain.43,45
This study presented some limitations. In order to obtain results 
for the base case population, several assumptions were made re-
garding clinical practice, patient's underlying condition and quality 
of life. Firstly, a conservative prevalence of 7.81% for IM patients 
with possible IA diagnosis was used in the model, but higher rates 
have been published reporting up to 10.7%.46 Secondly, assuming 
that the patients with IA had an underlying morbidity, the applica-
tion of the quality of life decrease associated to this morbidity had 
an impact in the results. Moreover, the model assumed that the 
patients surviving a fungal infection did not have any disutility due 
to the infection, and this might not reflect the real quality of life of 
these patients in the real world. Other assumptions are related to 
the decision tree and the numbers for mortality and treatments. The 
incidence of IM is low and there is a lack of data in the long-term 
consequences of antimycotic treatments, thus assumptions had to 
be made to overcome this lack of real data in the area.
Another limitation of this cost-effective analysis would be that 
the clinical parameters considered for IA patients were the same 
for both treatment arms (isavuconazole and voriconazole). Thus, 
the differences in QALYs and LYs are mainly due to the fact that 
voriconazole is not effective in treating IM, resulting in high mor-
tality rates for these patients because there is a delay in effective 
therapy initiation (at the time the pathogen is identified); together 
with an improvement in IA outcomes such as reduction in mortality, 
laboratory costs, adverse events and hospitalisations.
5  |  CONCLUSIONS
In conclusion, isavuconazole is cost-effective over voriconazole 
for the treatment of patients with possible IA. Considering the 
demonstrated efficacy of isavuconazole against Aspergillus spp. 
and Mucorales spp and its additional clinical benefits, these results 
strongly suggest that using isavuconazole instead of voriconazole 
could provide clinical and economic advantages for IA patients with-
out pathogen identification at the moment of therapy initiation and 
thus being beneficial for patients and for the Spanish NHS.
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